Palbociclib drug shows promise in women with HR+ metastatic breast cancer

[News]

Despite advances in managing and curing some forms of breast cancer, women whose disease becomes metastatic have fewer effective options. A new phase 3 study in some of the most difficult-to-treat patients, women with endocrine-resistant disease, showed that the newly approved drug, palbociclib, more than doubled the time to cancer recurrence for women with hormone-receptor (HR+) positive metastatic breast cancer.

More... (http://www.news-medical.net/news/20150530/Palbociclib-drug-shows-promise-in-women-with-HR2b-metastatic-breast-cancer.aspx)